Top

Published in:

01-12-2014 | Short Communication

Association of reduced XRCC2 expression with lymph node metastasis in breast cancer tissues

Authors: Nabiha Bashir, Syeda Sana, Ishrat Mahjabeen, Mahmood Akhtar Kayani

Published in: Familial Cancer | Issue 4/2014

Abstract

The main purpose of this study was to evaluate the association between reduction in XRCC2 gene and involvement of lymph node metastasis in breast cancer. In first part of the study, meta-analysis of 14 published XRCC2 studies was performed to define the role of XRCC2 gene as diagnostic marker and in second part of the study XRCC2 gene expression was observed using real time PCR in study cohort of 100 females (50 breast cancer patients and 50 controls). A statistically significant down regulation of XRCC2 (p < 0.04) and up-regulation of ki-67 (p < 0.05) was observed in breast cancer tissues compared to non-cancerous healthy tissues. In order to explore gene–gene and gene-clinicopathological parameters relationship Spearmen correlation was performed. We observed a significantly negative correlation between XRCC2 and Ki-67 expression (r = −0.376**, p < 0.01). In case of gene-clinicopathological parameters relationship, we observed a significant correlation between XRCC2 expression and lymph node status (r = −0.521***, p < 0.002) and metastatic status (r = −0.303*, p < 0.04) of breast cancer patients. Our data suggests that deregulation of XRCC2 in breast cancer has the potential to predict lymph node metastasis and may serve as a therapeutic target for breast cancer patients at risk of metastasis.

Available only for authorised users

Jiao L, Hassan MM, Bondy ML, Wolff RA, Evans DB, Abbruzzese JL, Li D (2007) XRCC2 and XRCC3 gene polymorphism and risk of pancreatic cancer. Am J Gatroenterol 103:360–367CrossRef

Curtin K, Lin WY, George R, Katory M, Shorto J, Cannon-Albright LA, Smith G, Bishop DT, Cox A, Camp NJ, Genetic Variants inXRCC2 (2009) New insights into colorectal cancer tumorigenesis. Cancer Epidemiol Biomarkers Prev 18:2476–2484PubMedCentralPubMedCrossRef

Mohindra A, Hays LE, Phillips EN, Preston BD, Helleday T, Meuth M (2002) Defects in homologous recombination repair in mismatch-repair deficient tumour cell lines. Hum Mol Genet 11:2189–2200PubMedCrossRef

Rodrigue A, Lafrance M, Gauthier MC, McDonald D, Hendzel M, West SC, Jasin M, Masson JY (2006) Interplay between human DNA repair proteins at a unique double-strand break in vivo. EMBO J 25:222–231PubMedCentralPubMedCrossRef

Phillips ER, McKinnon PJ (2007) DNA double-strand break repair and development. Oncogene 26:7799–7808PubMedCrossRef

Paul O, Wilson C, Townsend S, Thacker J (2001) XRCC2 Is a nuclear RAD51-like protein required for damage-dependent RAD51 focus formation without the need for ATP binding. J Biol Chem 276(25):22148–22153CrossRef

Simone B, Tuimala J, Christine B, Pierre D, Alain S, Ari H (2004) DNA repair gene XRCC2 and XRCC3 polymorphisms and susceptibility to cancers of the upper aerodigestive tract. Int J Cancer 112:901–904CrossRef

Park SJ, Byung B, Keun HN, Yoo Y (2008) Aetiology of cancer in Asia. APJCP 9:371–380PubMed

Cathryn ET, Karen GS, Caroline JR, Mark AH, John T (2010) The importance of XRCC2 in RAD51-related DNA damage repair. DNA Repair Cancer Res 9:517–525CrossRef

10.

Mahjabeen I, Chen Z, Zhou X, Kayani MA (2012) Decreased mRNA expression levels of base excision repair (BER) pathway genes is associated with enhanced Ki-67 expression in HNSCC. Med Oncol 29:3620–3625PubMedCrossRef

11.

Gong P, Wang Y, Liu G, Zhang J, Wang Z (2013) New insight into Ki67 expression at the invasive front in breast cancer. PLoS One 1:e54912CrossRef

12.

Varga Z, Diebold J, Dommann-Scherrer C, Frick H, Kaup D, Noske A, Obermann E, Ohlschlegel C, Padberg B, Rakozy C, Oliver SS, Schobinger-Clemen S, Schreiber-Facklam H, Singer G, Tapia C, Wagner U, Mastropasqua MG, Viale G, Lehr H (2012) How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the swiss working group of breast- and gynecopathologists. PLoS One 7:e37379PubMedCentralPubMedCrossRef

13.

Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca MS, Galimberti V, Veronesi P, Johansson H, Aristarco V, Bassi F, Luini A, Lazzeroni M, Varricchio C, Viale G, Bruzzi P, Decensi A (2012) Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 30:2593–2600PubMedCrossRef

14.

Sa´nchez-Rovira P, Anto´n A, Barnadas A, Velasco A, Lomas M, Rodríguez-Pinilla M, Ramírez JL, Ramírez C, Ríos MJ, Castellá E, García-Andrade C, San Antonio B, Carrasco E, Palacios JL (2012) Classical markers like ER and ki-67, but also survivin and pERK, could be involved in the pathological response to gemcitabine, adriamycin and paclitaxel (GAT) in locally advanced breast cancer patients: results from the GEICAM 2002-01 phase II study. Clin Transl Oncol 14:430–436CrossRef

15.

Benhamou S, Tuimala J, Bouchardy C, Dayer P, Sarasin A, Hirvonen A (2004) DNA repair gene XRCC2 and XRCC3 polymorphisms and susceptibility to cancers of the upper aerodigestive tract. Int J Cancer 112(5):901–904PubMedCrossRef

16.

Saviozzi S, Ceppi P, Novello S (2009) Non-small cell lung cancer exhibits transcript recombination and DNA replication pathways overexpression of genes associated with homologous. Cancer Res 6:3390–3396CrossRef

17.

Chang-Claude J, Ambrosone CB, Lilla C, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Popanda O (2009) Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer. Br J Cancer 100:1680–1686PubMedCentralPubMedCrossRef

18.

Bastos HN, Antao MR, Silva SN, Azevedo AP, Manita I, Teixeira V, Pina JE, Gil OM, Ferreira TC, Limbert E, Rueff J, Gaspar JF (2009) Association of polymorphisms in genes of the homologous recombination DNA repair pathway and thyroidcancer risk. Thyroid 19(10):1067–1075PubMedCrossRef

19.

Silva SN, Tomar M, Paulo C, Gomes BC, Azevedo AP, Teixeira V, Pina JE, Rueff J, Gaspar JF (2010) Breast cancer risk and common single nucleotide polymorphisms in homologous recombination DNA repair pathway genes XRCC2, XRCC3, NBS1 and RAD51. Cancer Epidemiol 34:85–92PubMedCrossRef

20.

Romanowicz H, Smolarz B, Baszczyński J, Zadrożny M, Kulig A (2010) Genetics polymorphism in DNA repair genes by base excision repair pathway (XRCC1) and association between polymorphisms of the RAD51-G135C, XRCC2-Arg188His and homologous recombination (XRCC2 and RAD51) and the risk of breast carcinoma in the Polish population. Pol J Pathol 61:206–212PubMed

21.

Krupa R, Sliwinski T, Wisniewska-Jarosinska M, Chojnacki J, Wasylecka M, Dziki L, Morawiec J, Blasiak J (2011) Polymorphisms in RAD51, XRCC2 and XRCC3 genes of the homologous recombination repair in colorectal cancer: a case control study. Mol Biol Rep 38:2849–2854PubMedCentralPubMedCrossRef

22.

Yin M, Liao Z, Huang YJ, Liu Z, Yuan X, Gomez D, Wang LE, Wei Q (2011) Polymorphisms of homologous recombination genes and clinical outcomes of non small cell lung cancer patients treated with definitive radio therapy. PLoS One 6:e20055PubMedCentralPubMedCrossRef

23.

Romanowicz-Makowska H, Smolarz B, Zadrozny M, Westfal B, Baszczynski J, Polac I, Sporny S (2011) Single nucleotide polymorphisms in the homologous recombination repair genes and breast cancer risk in Polish women. Tohoku J Exp Med 224:201–208PubMedCrossRef

24.

Romanowicz-Makowska H, Smolarz B, Zadrozny M, Westfa B, Baszczyński J, Kokołaszwili G, Burzyfiski M, Połać I, Sporny S (2012) The XRCC3-Thr241Met genes and clinico-pathologic features in breast cancer in Poland. Eur J Gynaecol Oncol 33:145–150PubMed

25.

Romanowicz-Makowska H, Smolarz B, Houli A, Szyłło K (2011) Single nucleotide polymorphism in DNA base excision repair genes XRCC1 and hOGG1 and the risk ofendometrial carcinoma in the Polish population. Pol J Pathol 62:89–94PubMed

26.

Butkiewicz D, Drosik A, Suwiński R, Krześniak M, Rusin M, Kosarewicz A, Rachtan J, Matuszczyk I, Gawkowska-Suwińska M (2012) Influence of DNA repair gene polymorphisms on prognosis in inoperable non-small cell lung cancer patients treated with radiotherapy and platinum-based chemotherapy. Int J Cancer 131:E1100–E1108PubMedCrossRef

27.

Romanowicz-Makowska H, Smolarz B, Gajęcka M, Kiwerska K, Rydzanicz M, Kaczmarczyk D, Olszewski J, Szyfter K, Błasiak J, Morawiec-Sztandera A (2012) Polymorphism of the DNA repair genes RAD51 and XRCC2 in smoking- and drinking-related laryngeal cancer in a Polish population. Arch Med Sci 8(6):1065–1075PubMedCentralPubMedCrossRef

28.

Fayaz S, Karimmirza M, Tanhaei S, Fathi M, Torbati PM, Fard-Esfahani P (2013) Increased risk of differentiated thyroid carcinoma with combined effects of homologous recombination repair gene polymorphisms in an Iranian population. APJCP 14(11):6727–6731PubMed

29.

Mohamed FZ, Hussien YM, AlBakry MM, Mohamed RH, Said NM (2013) Role of DNA repair and cell cycle control genes in ovarian cancer susceptibility. Mol Biol Rep 40:3757–3768PubMedCrossRef

30.

Petruzzelli GJ (2000) The biology of tumor invasion, angiogenesis and lymph node metastasis. ORL J Otorhinolaryngol Relat Spec 62(4):178–185PubMedCrossRef

31.

Kaisa R, Luoto AX, Meng ARW (2010) Genes that Control DNA Double-Strand Break Repair Tumor Cell Kill by c-MYC Depletion: role of MYC-Regulated. Can Res 70:8748–8759CrossRef

32.

Zheng Z, Wooi LN, Zhang X (2012) RNAi-Mediated Targeting of Noncoding and Coding Sequences in DNA Repair Gene Messages Efficiently Radiosensitizes Human Tumor Cells. Cancer Res 72(5):3254–3258CrossRef

33.

Margeli M, Cirauqui B, Castella E, Tapia G, Costa C, Gimenez-Capitan A, Barnadas A, Ronco MS, Benlloch S, Taron M, Rosell R (2010) The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer. PLoS One 5(3):1–9CrossRef

34.

Yuanming L, Lineng Z, Baorong S, Junjie P, Sanjun C (2013) BRCA1and ERCC1mRNA levels are associated with lymph node metastasis in Chinese patients with colorectal cancer. BMC Cancer 13:103–111PubMedCentralPubMedCrossRef

35.

Faratzis G, Tsiambas E, Rapidis AD, Machaira A, Xiromeritis K, Patsouris E (2009) VEGF and ki 67 expression in squamous cell carcinoma of the tongue: an immunohistochemical and computerized image analysis study. Oral Oncol 45:584–588PubMedCrossRef

36.

Kim SJ, Shin HJ, Jung K, Baek S, Shin BK, Choi J, Kim BS, Shin SW, Kim YH, Kim JS, Oosterwijk E (2007) Prognostic value of carbonic anhydrase IX and Ki-67 expression in squamous cell carcinoma of the tongue. Jpn J Clin Oncol 37:812–819PubMedCrossRef

37.

Liu X, Wang A, Muzio LL, Kolokythas A, Sheng S, Rubin C, Ye H, Shi F, Yu T, Crowe DL, Zhou X (2010) Deregulation of manganese superoxide dismutase (SOD2) expression and lymph node metastasis in tongue squamous cell carcinoma. BMC Cancer 10:365PubMedCentralPubMedCrossRef

38.

Inwald EC, Klinkhammer-Schalke M, Klinkhammer-Schalke F, Zeman F, Koller M, Gerstenhauer M, Ortmann O (2013) Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat 139:539PubMedCentralPubMedCrossRef

Title: Association of reduced XRCC2 expression with lymph node metastasis in breast cancer tissues
Authors: Nabiha Bashir
Syeda Sana
Ishrat Mahjabeen
Mahmood Akhtar Kayani
Publication date: 01-12-2014
Publisher: Springer Netherlands
Published in: Familial Cancer / Issue 4/2014
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-014-9745-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2014

Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment

Cribriform-morular variant of papillary thyroid carcinoma: an indication to screen for occult FAP

A primary care audit of familial risk in patients with a personal history of breast cancer

Germline CDKN2A mutations in Brazilian patients of hereditary cutaneous melanoma

The secondary bile acid, deoxycholate accelerates intestinal adenoma–adenocarcinoma sequence in Apc min/+ mice through enhancing Wnt signaling

High-resolution melting (HRM) assay for the detection of recurrent BRCA1/BRCA2 germline mutations in Tunisian breast/ovarian cancer families

Keynote webinar | Spotlight on antibody–drug conjugates in cancer